NanoViricides, Inc. (NYSE American: NNVC) announced the filing of its quarterly report for the period ended March 31, 2026, detailing continued progress of its broad-spectrum antiviral candidate NV-387 toward Phase II clinical development for MPox in the Democratic Republic of Congo (DRC), where regulatory approval for the trial has already been obtained. The company also outlined its orphan-first regulatory strategy, including FDA orphan drug designation for measles granted after the quarter and additional applications targeting MPox and smallpox.
The advancement of NV-387 is significant as it represents a potential treatment for multiple viral diseases, including respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, MPox, smallpox, and measles. According to the company, NV-387 is designed as a broad-spectrum antiviral drug that could address significant unmet medical needs, particularly in regions where these diseases are endemic or where treatment options are limited.
NanoViricides' focus on MPox in the DRC is notable given the recent global outbreak and the need for effective therapies. The DRC has experienced recurrent outbreaks, and the availability of a novel antiviral could have a substantial impact on public health. The company has secured regulatory approval to initiate Phase II trials in the country, marking a crucial step toward clinical validation.
In addition to MPox, NanoViricides received FDA orphan drug designation for measles, which provides incentives such as tax credits and market exclusivity. This designation underscores the potential of NV-387 to treat a disease that, despite being vaccine-preventable, continues to cause outbreaks worldwide. The company has also submitted applications for orphan drug status for MPox and smallpox, further expanding its regulatory strategy.
NanoViricides' technology is based on nanoviricide nanomedicines, which are designed to target viruses directly. The company's lead candidate, NV-387, is the active pharmaceutical ingredient in NV-CoV-2, a drug candidate for COVID-19. The company also has NV-CoV-2-R, which encapsulates remdesivir in polymeric micelles.
The announcement comes as NanoViricides continues to navigate the lengthy and capital-intensive drug development process. The company acknowledges that there can be no assurance that any of its candidates will demonstrate sufficient effectiveness and safety for human clinical development or eventual approval. However, the progress in the DRC and the orphan drug designations represent tangible milestones.
For more information on NanoViricides, visit the company's newsroom at https://ibn.fm/NNVC.
This news matters because it highlights the potential for a broad-spectrum antiviral to address multiple viral threats, which could have significant implications for global health security, especially in regions with limited healthcare infrastructure. The orphan drug designations also provide a pathway for expedited development and market access.
